Lucentis

Lucentis is a brand of medication used to treat various eye conditions, including neovascular (wet) age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion. The brand is produced by Genentech, a subsidiary of the Swiss pharmaceutical company Roche.

Lucentis contains the active ingredient ranibizumab, which is a recombinant humanized monoclonal antibody fragment. It works by blocking the activity of vascular endothelial growth factor (VEGF), a protein that promotes the growth of abnormal blood vessels in the eye. By inhibiting VEGF, Lucentis can help to reduce the formation of these abnormal blood vessels and improve vision in people with certain eye conditions.

Lucentis is administered by injection into the eye, typically by a healthcare professional such as an ophthalmologist. The frequency and duration of treatment depend on the individual’s specific condition and response to treatment. During treatment, patients will need to have regular eye exams and follow-up appointments to monitor their progress and adjust their treatment plan as needed.